Rommelag Engineering

Article

Sponsored Content

The scope of Rommelag’s bottelpack machines is virtually unlimited.

Canisters, bottles, tubes, ampoules, drop bottles, bellows containers, and portion packaging made of polyethylene, polypropylene, or plastic blends--the scope of Rommelag’s bottelpack machines is virtually unlimited. Bottelpack Blow-Fill-Seal machines are capable of manufacturing up to 34,000 containers an hour, with filling volumes ranging from 0.04 to 10,000 mL, aseptically, and taking all the applicable pharmaceutical regulations into account.

Rommelag USA, Inc.
27905 Meadow Drive, Suite 9,
Evergreen, CO 80439
mail.romus@rommelag.com 
AAPS Booth #2542

Recent Videos
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Nelson Labs Launches Rapid Sterility Testing, Cutting Incubation Times

Patrick Lavery
March 4th 2025
Article

The company now performs product-sterility testing through rapid microbiological methods at two laboratory sites in the United States and one in Germany.

Drug Solutions Podcast: Forecasting Pharma’s Future

Drug Solutions Podcast: Forecasting Pharma’s Future

Felicity Thomas
January 31st 2025
Podcast

This episode is a compilation of comments taken from a series of interviews where experts reveal the trends that have impacted the bio/pharma industry in 2024 and those they expect to be impactful in 2025.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Novartis Treatment for C3G Gets Positive Opinion from EMA

Patrick Lavery
March 4th 2025
Article

CHMP gave its opinion and a recommendation for marketing authorization to Fabhalta (iptacopan), an oral, Factor B inhibitor of the alternative complement pathway.

Drug Solutions Podcast: Realizing AI’s Potential

Drug Solutions Podcast: Realizing AI’s Potential

Felicity Thomas
December 20th 2024
Podcast

This episode is a compilation of comments taken from a series of interviews where experts are discussing how AI might impact the global bio/pharma industry in the future.

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

Pushing Tech Boundaries

Mike Hennessy Jr.
March 3rd 2025
Article

Artificial intelligence, among other technological advances, is pushing innovation boundaries.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

EMA Gives Positive Opinion to Lilly Treatment for Chronic Lymphocytic Leukemia

Patrick Lavery
March 3rd 2025
Article

Jaypirca (pirtobrutinib) has received a conditional marketing authorization from EMA for mantle cell lymphoma. The drug was approved in the United States in 2023 for several indications.